Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Recruiting No phase listed Observational

Application of the Patient-reported Longitudinal Assessment Tool for OSA (PLATO) Questionnaire in Oral Appliance Therapy for Obstructive Sleep Apnea

NCT07789834
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Oral Applliance Therapy
Interventions
The study will assess the feasibility of incorporating the PLATO questionnaire into a dental sleep practice. The PLATO questionnaire was developed as a patient reported outcome measure
Other
Lead sponsor
Nevada Dental Sleep
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Not listed Not applicable Interventional

UNITE Study (UCSD-SW) for COVID-19

NCT04803409
View directory record Official record
Conditions
Covid19
Interventions
Splenic Ultrasound
Device
Lead sponsor
Imanuel Lerman
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

NCT02959463
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab, Radiation Therapy
Other · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

NCT00698516
View directory record Official record
Conditions
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Interventions
Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Jonesboro, Arkansas • Gainesville, Florida • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139
View directory record Official record
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

NCT01987219
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

NCT04868500
View directory record Official record
Conditions
Asthma
Interventions
AMAZE™ Application, AMAZE™ Dashboard
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 31, 2026, 3:53 PM EDT
Not listed Not applicable Interventional

The Effect of Music Meditation Therapy in Patients With Chronic Pain Receiving Botox

NCT03532607
View directory record Official record
Conditions
Pain
Interventions
Music
Other
Lead sponsor
Rowan University
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 31, 2026, 3:53 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Active, not recruiting Phase 3 Interventional

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
36
States / cities
Daphne, Alabama • Chandler, Arizona • Prescott Valley, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional Results available

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

NCT04738487
View directory record Official record
Conditions
Lung Neoplasms, Non-Small-Cell Lung Carcinoma
Interventions
Pembrolizumab/Vibostolimab, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Boca Raton, Florida • Peoria, Illinois • Springfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

NCT04610047
View directory record Official record
Conditions
Influenza, Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 31, 2026, 3:53 PM EDT
Completed No phase listed Observational

Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins

NCT04514926
View directory record Official record
Conditions
Asthma, Therapeutic Proteins
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

The Evaluation of a New Nasal Mask for the Treatment of Obstructive Sleep Apnea

NCT04011826
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Device: Trial nasal mask (F&P)
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
22 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 31, 2026, 3:53 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

NCT03527108
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nivolumab, Ramucirumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00274547
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Not applicable Interventional Results available

Treatment for Migraines With an Implantable Device

NCT00286078
View directory record Official record
Conditions
Migraine
Interventions
Precision
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Denver, Colorado • Stamford, Connecticut • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 31, 2026, 3:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 3:53 PM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00041015
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 31, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

NCT00529035
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 31, 2026, 3:53 PM EDT
Terminated Phase 3 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

NCT03267108
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Open Label Extension
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 3:53 PM EDT